BBT-176 gets approval for Phase 1 and 2 trials by FDABridge Biotherapeutics said Monday that it has received approval from the U.S. Food and Drug Administration to start Phase 1 and 2 clinical trials for BBT-176.
BBT-176, a third-generation therapy for non-small cell lung cancer, will be tested with a small number of patients in Korea through a dose escalation study. The treatment from Bridge Biotherapeutics is separate from AstraZeneca’s Tagrisso.
BBT-176 will tested again in the United States and Korea. The studies will be used to observe safety, tolerability and anti-tumor efficacy of BBT-176 among patient groups.
The candidate substance, which was first discovered by the Korea Research Institute of Chemical Technology, was licensed to Bridge Biotherapeutics in late 2018.
By Ko Jun-tae